Phaos Technology Holdings (Cayman) Limited (POAS) AI Stock Analysis
POAS AI stock analysis summary
AI ResearchPhaos Technology Holdings (Cayman) Limited (POAS) is a Singapore-based medical devices company that develops and commercializes advanced microscopy-related products and software services. The company generated $132,077 in revenue over the trailing twelve months, reflecting a 3-year revenue CAGR of -41.2% from FY2023 to FY2026. Annual net losses reached -$6.2M in FY2026, alongside an operating margin of -4771.2%.
- Market cap
- $2.9M
- Revenue (TTM)
- $132,077
- P/E
- —
- 1Y return
- — S&P 500 16.8%
- Avg. target
- —
Bull case
- The company maintains a positive net cash balance of $311,196 as of July 31, 2026, with cash and short-term investments of $762,234 exceeding total debt of $451,038.
- Balance sheet liquidity shows a current ratio of 4.01 and a low debt-to-equity ratio of 0.09 as of July 31, 2026.
- The stock trades at a price-to-book ratio of 0.7x based on shareholders' equity of $5.3M.
Bear case
- Revenue has contracted at a 3-year CAGR of -41.2% from FY2023 to FY2026, falling to $132,077 in FY2026.
- The company generated an operating cash flow of -$10.9M and free cash flow of -$10.9M in FY2026.
- The stock has experienced severe price declines, posting a year-to-date return of -94.8% and closing at $2.65 compared to its 52-week high of $110.92.
What Phaos Technology does
Phaos Technology Holdings (Cayman) Limited, through its subsidiary Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano for viewing live and still images of larger sample areas, PT-Industrial for material study and quality control, and PT-Metrology for dimensional measurements. It also provides PT-Biology for biomedical imaging, PT-Stereo for magnified stereoscopic imaging of thick samples, and PT-Zoom for three-dimensional visualization. Additionally, the company offers software services to manufacturing companies, biomedical service providers, and research and development institutions.
Growth and profitability
Phaos Technology's annual revenue increased 189.3% in FY2024 to $1.9M before falling 91.1% in FY2025 to $167,707 and declining 21.2% in FY2026 to $132,077. Across this period, the 3-year revenue CAGR from FY2023 to FY2026 was -41.2%. Gross margin shifted from 17.6% in FY2023 to 47.7% in FY2024, then dropped to 22.1% in FY2025 and 13.1% in FY2026. Operating margin reached -4771.2% in FY2026, compared to -3148.3% in FY2025 and -132.9% in FY2024. Annual net income was -$1.7M in FY2023, -$2.4M in FY2024, -$5.1M in FY2025, and -$6.2M in FY2026. For the latest quarter ended July 31, 2026, quarterly revenue growth declined 57.5% year-over-year, while trailing twelve months EPS was -$5.72.
Balance sheet and cash flow
As of July 31, 2026, Phaos Technology held $762,234 in cash and short-term investments alongside total debt of $451,038, resulting in net cash of $311,196. The company reported shareholders' equity of $5.3M and a current ratio of 4.01, with a debt-to-equity ratio of 0.09. In FY2026, operating cash flow was -$10.9M and free cash flow was -$10.9M. Capital allocation in FY2026 included capital expenditures of $39,719 and share buybacks of $3.8M.
Valuation and performance
At a last close of $2.65 on October 16, 2026, Phaos Technology has a market cap of $2.9M and an enterprise value of $2.5M. The stock trades at a price-to-sales multiple of 22.0x and an EV-to-revenue multiple of 24.2x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.7x. The company's year-to-date return is -94.8%, trading 87.5% below its 200-day average, while the S&P 500 (SPY) delivered a 1-year return of 16.8% and a 5-year return of 83.0%.
What analysts expect
No Wall Street analyst rating counts, price targets, earnings estimates, or earnings surprise track records are available for Phaos Technology. The company also has no scheduled next earnings date reported. With a market cap of $2.9M, only 4.5% institutional ownership, and trailing twelve months EPS of -$5.72, the company does not have formal analyst coverage or published consensus forecasts.
Key risks and what to watch
- Free cash flow was -$10.9M in FY2026 against cash and short-term investments of $762,234 as of July 31, 2026, indicating ongoing liquidity pressure.
- Quarterly revenue growth fell 57.5% year-over-year in the quarter ended July 31, 2026, reflecting continued top-line contraction.
- Operating margin deteriorated to -4771.2% in FY2026, while trailing twelve months operating margin stood at -10747.8%.
- R&D expense was reduced to $0 in FY2026 from $139,720 in FY2025, which may impact future microscopy product innovation.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this POAS AI stock analysis
This page is an AI-written research summary of Phaos Technology Holdings (Cayman) Limited (POAS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: POAS income statement, POAS balance sheet, POAS key metrics, POAS chart. See the POAS stock overview for the latest quote and news.
POAS AI stock analysis FAQ
What microscopy products does Phaos Technology offer?
Phaos Technology offers Optonano for wide-area imaging, PT-Industrial for material analysis and quality inspection, and PT-Metrology for dimensional measurements. It also provides PT-Biology for biomedical imaging, PT-Stereo for magnifying solid samples, PT-Zoom for three-dimensional visualization, and related software services.
What was Phaos Technology's revenue and net income in FY2026?
In FY2026, Phaos Technology generated $132,077 in revenue, representing a 21.2% decrease from FY2025. The company recorded an annual net income of -$6.2M and an operating margin of -4771.2%.
How much cash and debt does Phaos Technology have?
As of July 31, 2026, the company held $762,234 in cash and short-term investments and total debt of $451,038, leaving net cash of $311,196. Its current ratio stood at 4.01 and debt-to-equity was 0.09.
Does Phaos Technology pay a dividend?
Phaos Technology does not pay a dividend. In FY2026, the company utilized cash for $39,719 in capital expenditures and $3.8M in share buybacks.